Allogene Surges 18.6%: Can This Biotech Rally Sustain Momentum?

Summary
• Allogene (ALLO) surges 18.6% at $2.455, far above its $2.13 intraday low
• Intraday turnover hits 9.29 million shares, signaling intense investor activity
• Biotech sector buzzes with AI-driven innovation and MaaT Pharma’s pivotal trial updates
Allogene is in the spotlight today, with its stock surging sharply from a morning low to a session high. This move is occurring amid a broader surge in biotech news, including major trial results and AI-driven drug design momentum. With the sector already showing signs of consolidation, investors are watching closely to see if this spike in ALLO is a breakout or a flash in the pan.

Options Activity and Short-Term Volatility Fuel Allogene’s Spike
Allogene’s dramatic intraday move reflects a surge in options activity and speculative positioning ahead of potential catalysts. The stock opened at $2.135 and quickly climbed to a session high of $2.6, driven by high-velocity call buying, particularly at the $2.5 strike. With implied volatility for near-term options reaching 170%, traders are clearly betting on a short-term move — likely in response to biotech’s AI-focused innovation wave and MaaT Pharma’s pivotal data release. This kind of options-driven action is often a precursor to a larger trend, especially when combined with the stock trading above its 30-day moving average and within a key breakout range.

Biotech Sector Gains Traction, BMY Pulls Back
While Allogene’s move is striking, the broader biotech sector shows mixed momentum. Sector leader Bristol-Myers Squibb (BMY) is down 0.37%, suggesting that the broader health care space is not uniformly bullish. This divergence highlights the speculative nature of Allogene’s rally, which appears more driven by near-term options positioning and AI-native biotech optimism than sector-wide momentum. Meanwhile, leveraged ETFs such as IBB and IBBQ are up less than 1.2%, indicating that while biotech is active, it is not yet leading the broader market.

Capitalizing on Allogene’s Volatility: Options and ETFs to Watch
• 200-day MA: 1.451 (far below current price), suggesting long-term undervaluation
• RSI: 32.1 (oversold territory), hinting at possible rebound
• Bollinger Bands: ALLO trading near upper band at $2.86, signaling short-term overextension
• MACD: 0.058 vs. Signal Line 0.135, bearish divergence in short term
• Turnover rate: 5.73% (high), indicating active positioning
Allogene is trading in a volatile breakout range, with key resistance at $2.6 and support at $2.13. The RSI hitting oversold levels and high turnover suggest a possible continuation of the rally — but only if the stock holds above $2.45. ETFs like IBB and IBBQ are modestly up, but their relatively low leverage makes them secondary plays. Instead, the real action is in options, particularly those with high gamma and theta decay, offering a short-term speculative edge. Here are two top options to consider:

• ALLO20260417C2.5: Call, Strike $2.5, Expiration 2026-04-17, IV 170.60%, Leverage 5.72%, Delta 0.579, Theta -0.0101, Gamma 0.349, Turnover 10,092
- High IV and moderate delta suggest volatility and sensitivity to price moves
- High gamma means it will react strongly to further upside
- Theta decay is aggressive, but the current trajectory favors holding
If ALLO continues upward, this call offers significant leverage with strong gamma, meaning it will accelerate in value as the stock moves. At a 5% price gain to $2.58, this contract could yield a 40%+ return.

• ALLO20260515C2.5: Call, Strike $2.5, Expiration 2026-05-15, IV 172.32%, Leverage 3.90%, Delta 0.624, Theta -0.0065, Gamma 0.233, Turnover 33,881
- Even higher IV and strong delta for a mid-term play
- High turnover and liquidity ensure easy entry and exit
- Moderate theta decay suggests it can be held for a few days without major erosion
This contract offers a slightly more measured approach with higher IV and better liquidity. With turnover at over 33k, it is one of the most actively traded options. If ALLO holds above $2.45 and moves toward $2.6, this contract could see strong gains with less time pressure. At 5% gain, it could yield ~30–35% profit.

With ALLO in a volatile breakout mode and key support levels intact, aggressive bulls may consider ALLO20260515C2.5 into a close above $2.5.

Backtest Allogene Stock Performance
The backtest of ALLO's performance after a 19% intraday surge from 2022 to now shows mixed results. While the stock experienced a maximum return of 0.05% during the 30-day period, the overall trend was negative, with a 3-day return of -0.28% and a 10-day return of -0.76%. The win rates for 3, 10, and 30 days were 44.69%, 46.42%, and 46.20%, respectively. This indicates that while there were some short-term gains, they were not consistently sustained, and the stock faced challenges in maintaining positive momentum.

Take the Bullish Edge: Allogene’s Momentum Could Be Just the Start
Allogene’s explosive intraday move — up 18.6% to $2.455 — is fueled by speculative options activity and broader AI-driven biotech optimism. With the stock near its 52-week high of $2.8 and trading above the 30-day average, the near-term technicals look bullish, especially if the stock holds above $2.45. The key to watching this trade is whether Allogene can close above $2.5 — a level that would confirm a breakout and validate the call options selected. Investors should also monitor sector leader Bristol-Myers Squibb (BMY), currently down 0.37%, for any signs of sector-wide strength. For now, the most compelling opportunity lies in leveraging Allogene’s short-term volatility through high-gamma, high-IV calls. If the stock maintains its upward trajectory, this move could mark the beginning of a larger trend — and options are the best way to capitalize.